1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

In Brief

ERSP clarifies requirements for quantified claims; food, veterinary medicine under same FDA office; FDA hosts forum on food safety regs; FDA OKs Reddy’s pediatric Allegra equivalent; Valeant finalizes Natur Produkt acquisition; FTC Chairman Jon Leibowitz to step down.

National Weight Loss Institute LLC substantiates claims that Prevoxin helped users lose 200% more weight than diet and exercise alone, according to the Electronic Retailing Self-Regulation Program. “Quantified percentage claims regarding product performance create very definitive expectations in the minds of consumers and marketers should be mindful that such claims must be corroborated,” ERSP says in a review of the weight-loss supplement released Jan. 30. NWLI met the requirement with two randomized, double-blind, placebo-controlled trials, ERSP found. One showed 200 mg daily of the product’s ingredient 7-Keto DHEA helped users lose twice as much as the placebo group and the other showed the users lost three times as much. However, because only one study showed the higher weight-loss level, ERSP determined the claim that users can lose “3X as much body fat” was not corroborated and should be discontinued.

The Council of Better Business Bureaus division, which reviewed NWLI’s advertising in its ongoing work, also supported claims Prevoxin “helps...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

Podium Policy Returns To US FDA, Or Is It Podcast Policy?

 
• By Michael McCaughan

US FDA critics have long decried the practice of using informal communications to convey regulatory expectations as podium policy. In the Makary era, the phrase may need to be updated because the agency now seems to be specializing in policy by podcast.

US FDA’s Elsa AI Platform Is Not Guiding Regulatory Decisions, Official Says

 
• By Cathy Kelly

Tala Fakhouri said the agency’s use of the AI tool in the review process has generated lots of questions.

Branch Chief Vijay Kumar Named Acting Head Of US FDA’s Cell, Gene Therapy Office

 
• By Derrick Gingery

Kumar takes over as acting director of the Center for Biologics Evaluation and Research’s Office of Therapeutic Products days after director Nicole Verdun was ousted.

Recent And Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

More from North America

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Woodcock: Do Not Do The Wrong Study, Even If Against US FDA Advice

 
• By Sarah Karlin-Smith

The former CDER director said she tells sponsors not to conduct an FDA-recommended study design or randomized trial if it will not work.

AI Will Bolster, Not Squelch, Patient Voice In Clinical Research, US FDA Says

 
• By Sue Sutter

Artificial intelligence tools used for clinical research should be developed with input from patients and focus on their needs and abilities, FDA experts said.